Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy

被引：0
|
作者：
Gillison, Maura L. [1 ]
Blumenschein, George, Jr. [2 ]
Fayette, Jerome [3 ]
Guigay, Joel [4 ]
Colevas, A. Dimitrios [5 ]
Licitra, Lisa [6 ,7 ]
Harrington, Kevin J. [8 ]
Kasper, Stefan [9 ]
Vokes, Everett E. [10 ]
Even, Caroline [11 ]
Worden, Francis [12 ]
Saba, Nabil F. [13 ]
Iglesias Docampo, Lara Carmen [14 ]
Haddad, Robert [15 ]
Rordorf, Tamara [16 ]
Kiyota, Naomi [17 ]
Tahara, Makoto [18 ]
Lynch, Mark [19 ]
Kopit, Justin [19 ]
Ferris, Robert L. [20 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Ctr Leon Berard, Lyon, France
[4] FHU OncoAge, Ctr Antoine Lacassagne, Nice, France
[5] Stanford Univ, Stanford, CA 94305 USA
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Milan, Milan, Italy
[8] Inst Canc Res, Royal Marsden NHS Fdn Trust, London, England
[9] Univ Hosp, West German Canc Ctr, Essen, Germany
[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[11] Gustave Roussy, Villejuif, France
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Hosp Univ 12 Octubre, Madrid, Spain
[15] Dana Farber Harvard Canc Ctr, Boston, MA USA
[16] Univ Spital Zurich, Zurich, Switzerland
[17] Kobe Univ Hosp, Kobe, Hyogo, Japan
[18] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [1] Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
    Gillison, Maura L.
    Blumenschein, George R.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis P.
    Saba, Nabil F.
    Docampo, Lara Carmen Iglesias
    Haddad, Robert I.
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Lynch, Mark John
    Kopit, Justin
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy
    Kasper, S.
    Gillison, M. L.
    Blumenschein, G.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Docampo, L. C. I.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Makoto, T.
    Lynch, M.
    Kopit, J.
    Ferris, R. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 96 - 96
  • [3] Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
    Ferris, Robert L.
    Licitra, Lisa
    Fayette, Jerome
    Even, Caroline
    Blumenschein, George, Jr.
    Harrington, Kevin J.
    Guigay, Joel
    Vokes, Everett E.
    Saba, Nabil F.
    Haddad, Robert
    Ramkumar, Shanmugasundaram
    Russell, Jeffery
    Brossart, Peter
    Tahara, Makoto
    Monga, Manish
    Zhu, Jin
    Colevas, A. Dimitrios
    Gillison, Maura L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 143 - 143
  • [4] ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    DeRosa, M.
    Cocks, K.
    Taylor, F.
    Bobiak, S.
    Garcia, Juarez A.
    Shaw, J. W.
    VALUE IN HEALTH, 2017, 20 (05) : A113 - A113
  • [5] Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
    Ferris, Robert L.
    Blumenschein, George R.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa F.
    Harrington, Kevin J.
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis P.
    Haddad, Robert I.
    Kiyota, Naomi
    Tahara, Makoto
    Monga, Manish
    Lynch, MarkJohn
    Geese, William J.
    Kopit, Justin
    Shaw, James W.
    Gillison, Maura L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
    Ferris, Robert L.
    Licitra, Lisa
    Fayette, Jerome
    Even, Caroline
    Blumenschein, George R.
    Harrington, Kevin
    Guigay, Joel
    Yokes, Everett E.
    Saba, Nabil F.
    Haddad, Robert I.
    Ramkumar, Shanmugasundaram
    Russell, Jeffrey
    Brossart, Peter
    Tahara, Makoto
    Monga, Manish
    Zhu, Jin
    Colevas, A. Dimitrios
    Gillison, Maura L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator's choice (IC): CheckMate 141
    Harrington, K.
    Ferris, R. L.
    Shaw, J.
    Taylor, F.
    Derosa, M.
    Turner-Bowker, D.
    Morrissey, L.
    Cocks, K.
    Kiyota, N.
    Gillison, M.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator's Choice (IC): CheckMate 141
    Kiyota, N.
    Harrington, K.
    Ferris, R. L.
    Shaw, J. W.
    Taylor, F.
    Derosa, M.
    Turner-Bowker, D.
    Morrissey, L.
    Cocks, K.
    Gillison, M.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Nivolumab (nivo) vs investigator's choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
    Saba, Nabil F.
    Blumenschein, George R.
    Guigay, Joel
    Licitra, Lisa F.
    Fayette, Jerome
    Harrington, Kevin J.
    Kiyota, Naomi
    Gillison, Maura L.
    Ferris, Robert L.
    Jayaprakash, Vijayvel
    Lynch, Mark John
    Li, Li
    Brossart, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis
    Hasegawa, Y.
    Kiyota, N.
    Takahashi, S.
    Yokota, T.
    Yen, C-J.
    Iwae, S.
    Shimizu, Y.
    Hong, R-L.
    Goto, M.
    Namba, Y.
    Ferris, R. L.
    Monga, M.
    Lynch, M.
    Hagihara, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345